Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
This study, published June 6 by Nature, marks the first demonstration in a living system that OxPL triggers inflammation and leads to plaque formation. The results also suggest a new approach for preventing or reversing a number of inflammatory diseases.
“Wherever you get inflammation, you get OxPL,” said senior author Joseph Witztum, MD, professor of medicine at UC San Diego School of Medicine. “It doesn’t mean OxPL is the cause, but it definitely plays a major role.” Witztum led the study with first author Xuchu Que, PhD, a senior project scientist at UC San Diego School of Medicine.
Some phospholipids — the molecules that make up cell membranes — are prone to modification by reactive oxygen species, forming OxPL. This event is particularly common in inflammatory conditions such as atherosclerosis, in which artery-blocking plaques form. Prior to this study, researchers were unable to control phospholipid oxidation in a way that would allow them to study its role in inflammation and atherosclerosis.
Witztum, Que and team engineered mice with two special attributes: 1) they have a gene mutation that makes them a good model for atherosclerosis and 2) they generate a piece of an antibody called E06 that’s just enough to bind OxPL and prevent their ability to cause inflammation in immune cells, but not enough to cause inflammation on its own. They fed the mice a high-fat diet.
Here’s what happened: Compared to control mice, the mice with E06 antibodies had 28 to 57 percent less atherosclerosis, even after one year and despite having high levels of cholesterol. The antibody also decreased aortic valve calcification (hardening and narrowing of the aortic valves), hepatic steatosis (fatty liver disease) and liver inflammation. E06 antibody-producing mice had 32 percent less serum amyloid A, a marker of systemic inflammation.
The E06 antibody also prolonged the life of the mice. After 15 months, all of the E06 antibody-producing mice were alive, compared to 54 percent of the control mice.
“We showed for the first time that OxPL are truly pro-inflammatory and pro-atherogenic and, moreover, that they can be counteracted by E06 antibody,” Witztum said. “This suggests that therapies that inactivate OxPL may be beneficial for reducing inflammation in general, and in particular in the case of diseases such as atherosclerosis, aortic stenosis and hepatic steatosis.”
Witztum and team are now testing E06 antibody in mouse models of human diseases linked to inflammation, such as osteoporosis (bone loss) and nonalcoholic steatohepatitis (NASH, a type of liver disease).
The Latest on: Inflammation
via Google News
The Latest on: Inflammation
- Cretaceous Titanosaur Suffered from Blood Parasites and Severe Bone Inflammationon December 1, 2020 at 12:42 pm
A giant sauropod dinosaur that lived 85.2 million years ago (Cretaceous period) in what is now Brazil had an aggressive case of osteomyelitis in its leg and soft-bodied parasitical microorganisms in ...
- Feed-induced gut inflammation and oxidative stress in chickens; what antibiotic growth promoters actually hideon November 30, 2020 at 11:39 pm
The ban or rejection of the use of antibiotic growth promoters (AGP) in poultry feed in many countries as well as the increasing restrictions on the use of antibiotics therapeutically are leading to a ...
- Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorderon November 30, 2020 at 6:30 pm
(NASDAQ:PHAT) has completed enrollment in a Phase 3 clinical trial, (PHALCON-EE), evaluating vonoprazan for both the healing and maintenance of healing of erosive esophagitis (EE) as well as the ...
- Eating foods that promote inflammation may worsen heart failureon November 30, 2020 at 1:18 pm
People with heart failure who eat a diet high in foods that cause inflammation are twice as likely to end up in the hospital or die as those who eat foods known to reduce inflammation, new research ...
- A Mendelian Randomization Study Suggests a Role for Inflammation and Metabolic Dysregulation in Suicidality and Depressionon November 30, 2020 at 7:20 am
Interleukin 6 overactivity could be associated with suicidality so interleukin-6 blockade may be a novel treatment target that warrants future research.
- Systemic inflammation increases over various stages of liver cirrhosis, shows studyon November 30, 2020 at 4:59 am
Patients with liver cirrhosis display a wide range of clinical symptoms. A prospective study conducted by MedUni Vienna has now shown that blood levels of biomarkers for systemic inflammation increase ...
- Inflammation caused by bacterial infection puts brain stem cells on alerton November 30, 2020 at 4:56 am
A study directed by Isabel Fariñas and published in the journal Cell Stem Cell reveals that the inflammation produced by a bacterial infection alerts brain stem cells and prepares their activation for ...
- Scientists find why some people with COVID-19 develop severe inflammationon November 29, 2020 at 3:19 am
In a new study, researchers found why some people with COVID-19 develop severe inflammation. They found how the molecular structure and sequence of the SARS-CoV-2 spike protein—part of the virus that ...
- The Medical Minute: What Research Tells Us About COVID-19, Heart Inflammationon November 27, 2020 at 10:21 pm
HERSHEY, Pa. — As the COVID-19 pandemic evolves, so too does research into its effects on heart health. One particular ...
via Bing News